Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA

The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.

An organophosphorus compound useful in a phosphorus containing flame retardant and a flame retardant polyurethane foam, where the organophosphorus compound is shown in Formula (I) where Y is selected from the group consisting of an —OH group, an —NH.sub.2 group, an —NHR.sup.3 group, and an —SH group, where R.sup.3 is a monovalent hydrocarbyl group having 1 to 10 carbon atoms; R is a divalent hydrocarbyl group; X is a heteroatom group; and R.sup.1 and R.sup.2 are each independently a substituted or unsubstituted hydrocarbyl group, wherein R.sup.1 and R.sup.2 can be optionally joined to form a ring. ##STR00001##

Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.

The electrolyte additive includes a neutral compound represented by formula (1) and having, in the molecule, a trialkyl silyl group. It can improve the withstand voltage of the electrolyte and be applied to electrolyte for lithium-ion rechargeable batteries. In formula (1), R.sup.1 each represent independent C1-8 alkyl groups, R.sup.2 each represent independent C1-8 alkyl groups, A represents a C1-10 alkylene group, X represents either a single bond, a methylene group or one of the linking groups represented by formulas (2) to (4), m represents an integer from 1 to 3, n represents an integer from 0 to 2, where m+n is 2 if X is a single bond, a methylene group, a linking group represented by formula (2) or a linking group represented by formula (3), and m+n is 3 if X is a linking group represented by formula (4). In formula (3), R.sup.3 represents a C1-8 alkyl group.

##STR00001##

Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.

The present disclosure relates to compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.

The present invention relates primarily to a process for producing particular phosphinates (phosphonous acid monoesters) and use thereof for producing biologically active substances which may be used in the pharmaceutical or agrochemical sector, preferably for producing phosphorus-containing amino acids.

Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA